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Pathological pain is a hyperexcitability disorder. Since the excitability of a neuron is set and controlled by a complement of ion
channels it expresses, in order to understand and treat pain, we need to develop a mechanistic insight into the key ion channels
controlling excitability within the mammalian pain pathways and how these ion channels are regulated and modulated in various
physiological and pathophysiological settings. In this review, we will discuss the emerging data on the expression in pain
pathways, functional role and modulation of a family of voltage-gated K+ channels called ‘M channels’ (KCNQ, Kv7). M channels
are increasingly recognized as important players in controlling pain signalling, especially within the peripheral somatosensory
system. We will also discuss the therapeutic potential of M channels as analgesic drug targets.
Abbreviations
BBB, blood–brain barrier; BNB, blood-nerve barrier; DH, dorsal horn; DRG, dorsal root ganglion; G9a, euchromatic histone-
lysine N-methyltransferase 2; PSNL, partial sciatic nerve ligation; REST, repressor element 1-silencing transcription factor;
SAR, structure–activity relationship; SIN3A, SIN3 transcription regulator family member A; TRPV1, transient receptor po-
tential cation channel subfamily V member 1; WDR, wide dynamic range; XE991, 10,10-bis(4-Pyridinylmethyl)-9(10H)-
anthracenone dihydrochloride
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Introduction
Pathological pain is a vast and unmet clinical problem, which
brings about poor quality of life for sufferers and puts a colossal
burden on healthcare systems worldwide. In European coun-
tries, national annual economic costs of chronic pain run into
billions and amounts to 3–10% of gross domestic products
(Breivik et al., 2013). The available statistics suggest that in the
United States, total incremental costs of health care due to pain
reaches up to hundreds of billions annually, which is higher
than the combined costs of cancer and diabetes (Anonymous,
2016). It is clear that other parts of the world are affected to a
similar degree, so pain is indeed a worldwide health, societal
and economic concern. Yet, despite years of research and in-
vestment, there is no ultimate clinical solution to pathological
pain and opioids, known to humanity since ancient times, are
still a gold standard. While in recent decades there has been a
dramatic progress in our understanding of the molecular and
cellular mechanisms of pain, the rational design of new thera-
pies based on this mounting knowledge is painstakingly slow.
Part of the problem is that most targets for current analgesics
are within the CNS and, thus, often cause cognitive and be-
havioural side effects and are subject to tolerance and addic-
tion issues. Current strategies for peripheral analgesia
involve the local application of fairly non-speciﬁc drugs (such
as the non-speciﬁc voltage-gated Na+ channel blockers,
e.g. lidocaine) or drugs that are speciﬁc for broadly expressed
targets [e.g. ziconotide, a conotoxin inhibitor of N-type
voltage-gated Ca2+ channels (Cav2.2 channels)]. These
strategies can be robust but often result in the complete loss of
sensory and motor ﬁbre activity. Drug discovery for new
analgesics mostly focuses on targets that are ‘speciﬁc’ for
nociceptive neurons, but this has also proven difﬁcult due to
either widespread expression patterns [such as, for example
with TRPV1 (Lee et al., 2015)] or the existence of closely
related isoforms in other tissues (such as with the voltage-
gated Na+ channels; Wood, 2013). Therefore, new ideas for
therapies and new molecular targets for these therapies are
urgently needed.
Here, we review the current literature on the expression in
pain pathways, functional role and a potential for therapeutic
targeting of a family of K+ channels called ‘M channels’
(KCNQ, Kv7), which are increasingly recognized as one of
the important mechanisms controlling nociceptive ﬁbre ac-
tivity. Several earlier reviews on this or related topics are avail-
able (Munro and Dalby-Brown, 2007; Gribkoff, 2008; Rivera-
Arconada et al., 2009; Wickenden and McNaughton-Smith,
2009; Du and Gamper, 2013; Wang and Li, 2016), so here,
we will focus on recent developments in the ﬁeld as well as
on the emerging understanding of the sites of analgesic efﬁ-
cacy of M channel potentiating drugs (‘openers’) within the
mammalian nervous system. Since most of the available evi-
dence concerns the M channels expressed within the periph-
eral somatosensory system, we will mainly focus on the role
of M channels in peripheral pain pathways.
M channels: ﬁt to control
M channels (Kv7.1–Kv7.5 coded for by KCNQ1-KCNQ5
genes) are voltage-gated K+ channels with interesting
biophysical properties affecting neuronal excitability
(Figure 1; Delmas and Brown, 2005; Gamper and Shapiro,
2015). In particular, they have a very negative threshold for
activation, do not inactivate and have slow activation and de-
activation kinetics. If the density of Kv7 channels is sufﬁ-
ciently large (relative to the density of ‘leak’ channels, or
other channels that open around the resting potential), they
may contribute to the resting potential of a neuron (Delmas
and Brown, 2005; Huang and Trussell, 2011; Du et al.,
2014). As a result, M channel inhibition causes depolariza-
tion, a reduction in the threshold current and rheobase and
an increase in input resistance, while their activation
hyperpolarizes neuronal plasma membrane and reduces
input resistance, making the neuron more resistant to ﬁring
action potentials (Figure 1; Gamper and Shapiro, 2015).
Numerous reports indeed conﬁrm that acute Kv7 channel
inhibition leads to increased excitability of various types of
central and peripheral neurons while loss-of-function muta-
tions in KCNQ genes results in debilitating excitability
disorders such as epilepsy, deafness and cardiac arrhythmia
(reviewed in Jentsch, 2000; Delmas and Brown, 2005;
Gamper and Shapiro, 2015).
M channels in neurons are inhibited by stimulation of
muscarinic ACh receptors (M receptors) and, therefore,
serve as a mechanism for the excitatory action of the neuro-
transmitter ACh (Brown and Adams, 1980). By now, it is
ﬁrmly established that M1, M3 and M5 receptors, as well as
many other GPCRs of a similar type (e.g. bradykinin B2,
purinergic P2Y and angiotensin II AT receptors), inhibit M
channels (Shapiro et al., 1994; Cruzblanca et al., 1998;
Filippov et al., 2006; Zaika et al., 2006, 2007; Linley et al.,
2008; Gamper and Shapiro, 2015) and cause excitatory ac-
tions in neurons of different types, including the nociceptors
(Crozier et al., 2007; Linley et al., 2008; Liu et al., 2010). These
GPCRs are coupled to Gq/11 type of Gα and to PLC. The signal-
ling pathways linking the Gq/11-coupled receptor activation
with the M channel inhibition have been a subject of intense
research over the past few decades and are largely outside the
scope of this review (in-depth reviews on this topic are avail-
able; Gamper and Shapiro, 2007, 2015; Hernandez et al.,
2008; Hille et al., 2015; Greene and Hoshi, 2016). The major
mediators of the inhibition are believed to be (i) the depletion
of membrane phosphoinositide PIP2, a factor that is
necessary for M channel activity (Suh and Hille, 2002;
Zhang et al., 2003; Li et al., 2005); (ii) Ca2+ release from the
IP3-sensitive Ca
2+ stores (Cruzblanca et al., 1998; Gamper
and Shapiro, 2003; Kosenko and Hoshi, 2013); and (iii)
PKC-mediated M channel phosphorylation (Hoshi et al.,
2003; Zhang et al., 2011b). This GPCR-mediated M channel
suppression is at the core of the role these channels play in
the development of persistent inﬂammatory pain (see below).
M channel expression in peripheral
nociceptive pathways
Peripheral somatosensory neurons are the longest cells in our
body (on par with motor neurons) and have a complex,
pseudo-unipolar morphology (schematized in Figure 2). A so-
matosensory neuron can be subdivided into at least four spe-
cialized compartments: (i) a peripheral ending within the
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innervated tissue (skin, epithelia, muscles, etc.); (ii) a very
long axon (ﬁbre); (iii) a central terminal synapsing in the spi-
nal cord; and (iv) a cell body within sensory ganglia. All four
compartments have distinct functional roles and distinct an-
atomical locations (e.g. central terminals are within the CNS
while other parts belong to the PNS). Functional M channels
are expressed in all these compartments. Thus, dorsal root
ganglion (DRG) and trigeminal ganglion (TG) neuron cell
bodies generate sizable M currents (Passmore et al., 2003;
Rose et al., 2011; King and Scherer, 2012; Zheng et al.,
2013; Du et al., 2014), whereas M channel openers reduce
and M channel blockers increase somatic excitability of
these sensory neurons (Figure 1B, C; Liu et al., 2010; Linley
et al., 2012a,b; Du et al., 2014). Functional expression of M
channels is conﬁrmed in peripheral sensory axons (Devaux
et al., 2004; Rose et al., 2011; Roza et al., 2011; King and
Scherer, 2012; Passmore et al., 2012; Peiris et al., 2017),
including human sural nerve C ﬁbres (Lang et al., 2008)
and human colonic afferents (Peiris et al., 2017). Functional
M channels are also reported in nociceptive dorsal
roots/central terminals (Rivera-Arconada and Lopez-Garcia,
2006) as well as in nociceptive peripheral nerve endings
(Linley et al., 2008; Liu et al., 2010; Passmore et al., 2012;
Vetter et al., 2013). The relative expression levels and rela-
tive functional activity of M channels at these distinct com-
partments of a peripheral somatosensory neuron are hard to
evaluate at present; in case of myelinated ﬁbres, it has been
reported that Kv7.2 and Kv7.3 subunits are concentrated at
the nodes of Ranvier (Devaux et al., 2004; Roza et al., 2011;
King and Scherer, 2012).
The Kv7 subunit expression proﬁles in ﬁbres with differ-
ent sensory modalities are still poorly characterized and even
controversial. It is logical to expect that nociceptors, which
have intrinsically high ﬁring thresholds, would express more
functional M channels as compared to low-threshold, non-
nociceptive neurons (e.g. low-threshold mechanoreceptors,
proprioceptors, etc.) as the M current is one of the neuronal
mechanisms that raises threshold current (see Figure 1); how-
ever, this is yet to be conﬁrmed experimentally. The original
report describing M channel expression in DRG (Passmore
et al., 2003) documented the expression of Kv7.2, Kv7.3 and
Kv7.5 in nociceptive and non-nociceptive DRGneurons with
Kv7.2 and Kv7.3 being predominant subunits. In our studies,
we found that Kv7.2 was indeed more robustly expressed in
small-diameter DRG neurons and non-myelinated ﬁbres with
less abundant (although still detectable) expression in larger
neurones (Rose et al., 2011; Huang et al., 2016a). Other stud-
ies also reported expression of Kv7.2 in nociceptive C- and
Aδ ﬁbres (Wladyka et al., 2008; Passmore et al., 2012); in addi-
tion, the expression of Kv7.5 was found in larger, myelinated
ﬁbres (Wladyka et al., 2008). However King and Scherer
(2012) came to the opposite conclusion with regard to Kv7.2
and Kv7.5 expression: they found that Kv7.2 is expressed at
higher levels in larger, presumably non-nociceptive, neurons
while small-diameter DRG neuron cell bodies and C ﬁbres
expressed lower levels of Kv7.2 but high levels of Kv7.5.
The pharmacological proﬁle of M currents recorded from
cultured nociceptive DRG neurons speaks against a strong
contribution of Kv7.5, since native M currents in DRG neu-
rons display reasonable sensitivity to XE991 (Passmore
et al., 2003, 2012; Linley et al., 2008, 2012a; Rose et al.,
Figure 1
Role of M channels in sensory neurons from a biophysical perspec-
tive. (A) Schematized voltage-dependence of an M channel (Kv7.2/
Kv7.3) with relation to the resting membrane potential and ﬁring
threshold of a generalized C-ﬁbre nociceptor. Inset showsM currents
recorded in a CHO cell, overexpressing Kv7.2 and Kv7.3, in response
to the voltage steps depicted in the diagram above the traces. (B)
Simulation of the effect of modulation of M channel (Kv7.2/Kv7.3)
activity with an ‘opener’, retigabine and blocker, XE991, on steady-
state membrane potential. Steady-state membrane potential (Vm)
arises when net current across the plasma membrane is zero (in this
example, for only ‘M’ and leak currents). Varying M channel volt-
age-dependence and maximum conductance (GM) shifts Vm (leak
currents were kept constant). Parameters for Vrest, retigabine and
XE991 were obtained from Linley et al. (2012b). (C) Current-clamp
recording of the effect of retigabine and XE991 on the Vm recorded
from a cultured small-diameter rat nociceptor in current-clamp
mode (modiﬁed from Du et al., 2014, with permission). (D) Effects
of retigabine and XE991 on the ﬁring threshold and frequency of a
cultured small-diameter mouse nociceptor; stimulus ramp is shown
below the traces.
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2011), as do the heterologousely overexpressed Kv7.2 and
Kv7.3 channels, while Kv7.5 has a weaker sensitivity to this
blocker (Schroeder et al., 2000). This, however, does not ex-
clude the possibility that Kv7.5 contribute to some extent,
as channels expressed in cultured DRG neurons may not be
equivalent to those expressed in native tissue. Future studies
will have to resolve this controversy as well as establishing
the exact Kv7 subunit expression proﬁles in somatosensory
ﬁbres of different modalities. This is indeed an important task
as it can hold the key to the development of subunit-speciﬁc
M channel openers, optimized for targeting channels in
peripheral ﬁbres for pain relief (see below).
In addition to the above ﬁndings, in another study it
was demonstrated that a deﬁned subpopulation of
cutaneous mechanoreceptors (rapidly adapting hair follicles
and Meissner corpuscles) speciﬁcally expresses Kv7.4
(Heidenreich et al., 2012).
M channels and peripheral ﬁbre
excitability in vitro, in silico and in vivo
There are very clear and undisputed effects of M channel
activity on the somatic excitability of cultured DRG and TG
neurons (Passmore et al., 2003; Crozier et al., 2007; Linley
et al., 2008, 2012a,b; Liu et al., 2010; Mucha et al., 2010;
King et al., 2014; Figure 1C). Yet, since cultured sensory
neurons are axotomized and are grown in artiﬁcial condi-
tions, their physiology may not necessarily accurately rep-
resent those of native neurons, since gene expression may
be different. Therefore, a higher level of conﬁdence regard-
ing the functional role of M channels in sensory neuron
excitability is gained from acute preparations, such as
skin-nerve preparations and sectioning of acutely dissected
ganglia/nerves.
M channel activity and excitability of spinal
nociceptors
Depolarization by the M channel inhibitor, XE991 and hy-
perpolarization by an M channel activator (‘opener’)
retigabine has been recorded from capsaicin-sensitive
neurons using sharp-electrode recordings from acute DRG
slices (Du et al., 2014). In a skin-saphenous-nerve prepara-
tion, retigabine markedly reduced noxious heat responses of
the mechano-heat Aδ- and some C-ﬁbres (the latter to a some-
what lesser extent), while XE991 increased noxious heat sen-
sitivity and induced ongoing activity at 32°C in Aδ ﬁbres
(Passmore et al., 2012). A similar skin-saphenous-nerve prep-
aration has been used to demonstrate that M channel inhibi-
tion (e.g. by XE991, camphor or menthol) ampliﬁed cold
transduction by a speciﬁc population of C ﬁbre nociceptors:
Figure 2
Simpliﬁed schematic of a nociceptive neuron. Dotted boxes encircle areas where functional M channel activity has been recorded in situ using
slices (spinal cord, DRG) or skin-nerve preparations. Examples of recordings from such preparations are also shown as follows: (a) the effects of
retigabine and XE991 on heat-induced Aδ ﬁbre activity recorded in skin-saphenous-nerve preparation (modiﬁed from Passmore et al., 2012, with
permission); (b) the effect of the same compounds on the resting membrane potential of a capsaicin-sensitive neuron recorded from the DRG
‘slice’ using a sharp electrode recording (modiﬁed fromDu et al., 2014, with permission); (c) the effect of ﬂupirtine on the 4-AP-induced excitatory
activity recorded extracellularly from substantia gelatinosa in rat spinal cord (modiﬁed from Visockis and King, 2013, with permission).
Abbreviations: 4-AP, 4-aminopiridine; RTG, retigabine, SC, spinal cord.
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TRPM8-expressing C-mechano-cold ﬁbres (Vetter et al.,
2013). In the same ﬁbres, retigabine inhibited cold-evoked
activity. In another study, the multi-unit recordings of the
lumbar splanchnic nerve in a colon-nerve preparation
demonstrated that the noxious distension-induced ﬁring
was reduced by retigabine and increased by XE991 (Peiris
et al., 2017). Collectively, these studies indicate that M
channel activity does strongly affect the excitability of
acutely isolated spinal Aδ and C ﬁbres.
Although indicative, in vitro tests fall short of demonstrat-
ing how strongly, if at all, native M channel activity contrib-
utes to peripheral nociceptive transmission in vivo. Yet there
is growing evidence suggesting that this is indeed the case.
Thus, plantar hind paw injections of the M channel blocker,
XE991, induce moderate pain in rats (Linley et al., 2008; Liu
et al., 2010). In accord with this, plantar injections of XE991
increased ﬁring of wide dynamic range (WDR) dorsal horn
(DH) neurons in response to both mechanical and thermal
stimulation of the hind paw in spinal cord recordings in
anaesthetized animals (Passmore et al., 2012). Moreover, hind
paw injection of retigabine reduced thermal sensitivity in
freely behaving animals (Huang et al., 2016a) and also greatly
reduced pain produced by local (hind paw) injections of the
inﬂammatory mediator bradykinin (Liu et al., 2010; Huang
et al., 2016a).
A recent computational study provided a biophysical
foundation to these and similar observations by utilizing
a multi-component model of rat C ﬁbre that included a
geometrically realistic nociceptive nerve ending in the skin
(Barkai et al., 2017). When sufﬁciently pronounced, M
channel inhibition resulted in ‘spontaneous ﬁring’.
Whereas almost complete inhibition was required for spike
generation in the soma, a less dramatic decrease (to just
below 37%) was required to produce ‘spontaneous’ ﬁring
in a nociceptive terminal. The modelling also showed that
M current actively prevented excitation of nociceptive
terminals in response to a range of subthreshold depolar-
izations and fairly large (up to 15 mV) ‘spontaneous’
ﬂuctuations of resting membrane potential. When reduced
to 50% of ‘basal’ density, M current still prevented sponta-
neous ﬁring, but such a reduction dramatically potentiated
responses to noxious stimulation (e.g. with simulated
‘capsaicin’).
M channel activity and excitability of
trigeminal nociceptors
Kv7.2 immunoreactivity (Abd-Elsayed et al., 2015) and siz-
able M currents were reported in small-diameter TG neurons
in culture (Linley et al., 2012a, b; Ooi et al., 2013;
Abd-Elsayed et al., 2015) and in the whole-cell patch clamp
recordings from acute whole-mount trigeminal ganglia
(Kanda and Gu, 2017). These studies showed that, similar
to spinal neurons, M channels are involved in setting resting
membrane potential and rheobase in cold-sensing TG
nociceptors (Abd-Elsayed et al., 2015) and also in most
neurons that are sensitive to cold but are not primarily
cold-sensing (Kanda and Gu, 2017). Interestingly, it was also
reported that inhibition of M channel activity by cold
contributes to cold sensitivity of the latter type of neurons.
Retigabine (i.p.) alleviated cold hyperalgesia in two orofacial
neuropathic pain models (Abd-Elsayed et al., 2015), further
supporting the active role M channels play in the control
of trigeminal nociceptor excitability in vivo. In addition to
the above studies, Linley et al. (2012a) analysed the
unexpected potentiation of M channel activity by
substance P in TG and DRG neurons and found that,
mechanistically, the modulation was similar in both types
of sensory neurons.
M channels in nociceptive mechanotransduction
The studies discussed above established a role for M chan-
nels in modulating the sensitivity of peripheral nociceptive
ﬁbres to heat and cold. However, the role of M channels in
mechanical sensitivity is less certain. In skin-saphenous-
nerve preparations from naïve CD1 mice, retigabine had
no signiﬁcant effect on ﬁring in response to mechanical
stimulation of either slowly or rapidly adapting mechano-
sensitive Aδ and C ﬁbres, while two out of four rapidly
adapting Aδ ﬁbres responded to XE991 with increased ﬁring
rate (Roza and Lopez-Garcia, 2008). However, in the same
study, retigabine strongly suppressed ﬁring in axotomized
mechanically-sensitive ﬁbres of either type. Mice with
genetic deletion of Kcnq2 in cells derived from the neural
crest (including DRG neurons) displayed both thermal and
mechanical hyperalgesia (King et al., 2014). Consistently,
in another study, mice with global genetic deletion of
Kv7.3 (Kcnq3
/) and down-regulation of Kv7.2 (Kcnq2
+/)
displayed increased ﬁring rates of mechanosenstive D-hairs
(Aδ-low-threshold mechanoreceptors) in response to
mechanical stimulation (Schutze et al., 2016). Yet the effect
was modest and no obvious behavioural phenotype was
reported (although this could have been due to only partial
loss of Kv7.2). Finally, it was also reported that peripheral
nerve endings of rapidly adapting cutaneous hair follicles
and Meissner corpuscle mechanoreceptors from mice and
humans abundantly express Kv7.4 (Heidenreich et al.,
2012). Moreover, mice with genetic deletion of Kcnq4
displayed increased sensitivity of rapidly adapting mecha-
noreceptors to low-frequency vibration. In accord with
these ﬁndings, humans with DFNA2 (a slowly progressing,
autosomal dominant form of hearing loss) due to loss-of-
function mutations in KCNQ4 were better than age-
matched controls at detecting low frequency skin vibration
(Heidenreich et al., 2012). Altogether, these data suggest
that the contribution of Kv7 subunits to the modulation of
mechanical sensitivity varies in different types of mechano-
receptors; however, elucidation of the exact role of M chan-
nels in the mechanosensitivity of peripheral afferents (and
how it might change in pathological pain states) requires
further research.
M channel suppression as a general
mechanism for peripheral nerve
hyperexcitability
The ﬁndings discussed above established that (i) M channels
control the excitability of neurons that express them at sufﬁ-
cient levels; (ii) loss of M channel function results in an
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overexcitable neuron; and (iii) at least some peripheral
nociceptive ﬁbres express sufﬁcient levels of functional Kv7 sub-
units for these to inﬂuence ﬁbre excitability. The most logical
projection from these conclusions is that inhibition, down-
regulation or any other form of loss of M channel function in
nociceptive ﬁbres might result in increased excitability,
nociception and pain.On the other hand, peripheralM channel
activation could be analgesic. Below, we will consider growing
experimental evidence supporting the above considerations.
Inflammatory pain
As mentioned earlier, many Gq/11-coupled GPCRs were shown
to acutely and potently inhibit M channel activity. Tissue
inﬂammation brings about a speciﬁc environment, in which
inﬂamed/damaged tissue as well as cells involved in the im-
mune response release various chemical factors (inﬂammatory
mediators; e.g. prostaglandins, leukotrienes, interleukins, bra-
dykinin, substance P, ATP, growth factors, proteases, protons
and nitric oxide) in order to orchestrate defensive and
reparative processes or as a result of the loss of tissue integrity
(Serhan and Savill, 2005; Ferrero-Miliani et al., 2007). These
same factors often ‘sensitize’ or even directly excite nociceptive
afferents triggering inﬂammatory pain and hyperalgesia. Many
of the receptors of these inﬂammatorymediators areGPCRs that
are coupled to the Gq/11-PLC signalling pathway (similar to
muscarinic M1 receptors). These include B2 receptors (Couture
et al., 2001; Petho and Reeh, 2012), histamine H1 recep-
tors (Kuhn et al., 1996), protease-activated receptor-2
(PAR2; Bushell et al., 2006), prostaglandin EP1 (Breyer et al.,
1996) and P2Y (Chen and Chen, 1997) receptors (reviewed in
Linley et al., 2010). Bradykinin can be considered as one of the
prototypic Gq/11 coupled inﬂammatory mediators as it is
released upon tissue damage and inﬂammation; its receptors
are abundantly expressed in nociceptors; and bradykinin
injections or topical applications to wounds/blisters are very
painful (Keele, 1967; Dray and Perkins, 1993; Liu et al., 2010;
Petho and Reeh, 2012; Linley et al., 2012a). Bradykinin is so
active that it has been branded ‘the most potent endogenous
algogenic substance ever identiﬁed’ (Dray and Perkins, 1993).
Bradykinin is known to inhibit M channels in expression
systems and sympathetic and sensory neurons (Cruzblanca
et al., 1998; Gamper and Shapiro, 2003; Zhang et al., 2003;
Liu et al., 2010; Linley et al., 2012a). Thus, in cultured DRG
neurons, bradykinin inhibited M current by 50–60% and in-
creased their excitability, effects that were mimicked by
XE991 and antagonized by a retigabine analogue, ﬂupirtine
(Liu et al., 2010; Linley et al., 2012a). In accord with these
ﬁndings, hind paw injections of bradykinin produced promi-
nent pain-like (‘nocifensive’) behaviour in rats, an effect that
can be attenuated by retigabine or mimicked by XE991 (Liu
et al., 2010; Zhang et al., 2015; Huang et al., 2016a). Bradyki-
nin was recently also shown to robustly excite colonic affer-
ents, and this effect was also abolished by retigabine and
partially mimicked by XE991 (Peiris et al., 2017). It has to be
noted that M current inhibition is not the sole excitatory ac-
tion of bradykinin in DRG neurons; B2 receptor stimulation
also results in the activation of the excitatory chloride chan-
nel, TMEM16A (Liu et al., 2010; Jin et al., 2013), sensitiza-
tion of TRPV1 (Sugiura et al., 2002) and TRPA1 (Bandell
et al., 2004) channels as well some additional effects,
including trafﬁcking of pro-excitatory channels (Huang
et al., 2016b; reviewed in Petho and Reeh, 2012).
Similarly to bradykinin receptors, stimulation of PAR2
(Linley et al., 2008) and Mrgprd (Crozier et al., 2007) recep-
tors also inhibits M channels in nociceptive DRG neurons,
an effect that contributes to the inﬂammatory pain and itch
mediated by these inﬂammatory GPCRs.
Neuropathic pain
Neuropathic pain is deﬁned as ‘pain caused by a lesion or dis-
ease of the somatosensory nervous system’ (International As-
sociation for the Study of Pain, 2017); it is caused by injuries
or degeneration within peripheral or central somatosensory
pathways. Among chronic pain conditions, neuropathic pain
is one of the most debilitating and also one of the most resil-
ient to treatment as it often responds poorly to medication
(O’Connor and Dworkin, 2009). Neuropathy is associated
with spontaneous and evoked pains that often persist over
long periods of time (Campbell and Meyer, 2006). Both pe-
ripheral and central mechanisms contribute to the develop-
ment of neuropathic pain. A state of sustained pathological
overexcitability of nociceptive afferents (‘peripheral sensiti-
zation’) is considered necessary for the development of most
types of neuropathic pain.
When peripheral axons are severed (e.g. by trauma), the
nerve stump forms a swelling or endbulb, which then sprouts
thin processes, which may re-connect severed nerve endings,
if these are in close enough proximity. If regeneration is
obstructed, the endbulb, aborted sprouts and surrounding
glia become a bulky tissue formation called a neuroma
(Fawcett and Keynes, 1990; Devor, 2006). Both the neuroma
(Govrin-Lippmann and Devor, 1978; Wall and Devor, 1983)
and cell bodies of damaged nerves (Wall and Devor, 1983;
Amir and Devor, 1997; Liu et al., 2000) generate spurious ec-
topic ﬁring, which may cause pain on its own but also feeds
into the spinal wind-up mechanisms. The neuropathic defor-
mation of the injured nerve is associated with large-scale re-
modelling of the injured and perhaps also neighbouring,
uninjured ﬁbres within the affected nerve and the corre-
sponding sensory ganglion. One of the striking features of
such remodelling is a marked down-regulation of several
key K+ channel genes (including Kcnq2 and Kcnq5) (Rose
et al., 2011; King and Scherer, 2012; Du and Gamper, 2013;
Cisneros et al., 2015; Laumet et al., 2015). Such a loss of K+
channels is expected to result in depolarized and more excit-
able ﬁbres, which is indeed one of the characteristic of neuro-
pathic afferents and, also, of the DRG neurons from mice
with the genetic deletion of Kv7.2 from sensory neurons
(King et al., 2014). The mechanisms underlying the down-
regulation of K+ channel genes following nerve injury are un-
der intense scrutiny, and several molecular players have been
identiﬁed. Thus, we found that a down-regulation of Kcnq2
expression triggered by the partial sciatic nerve ligation
(PSNL) in rat DRG is dependent on repressor element
1-silencing transcription factor (REST, also known as NRSF)
(Rose et al., 2011). Kcnq genes have functional repressor ele-
ment 1 (NRSE) binding sites (Mucha et al., 2010; Iannotti
et al., 2012). Accordingly, viral overexpression of REST in
DRG neurons strongly suppressed M current density and in-
creased their tonic excitability (Mucha et al., 2010). REST in-
hibits transcription by recruiting co-repressor complexes
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SIN3A/B and REST corepressor 1; these complexes, in turn,
modify target gene regions through chromatin-modifying
enzymes, including histone deacetylases 1/2 (HDAC1/2),
the histone demethylase LSD1 and the histone methylase
G9a (Ooi and Wood, 2007; Willis et al., 2016). Interestingly,
inhibition or genetic deletion of G9a in DRG was shown to
abolish the down-regulation of Kv7.2 [as well as three other
K+ channels: Kv1.4, Kv4.2 and BK channels (KCa1.1)] in-
duced by neuropathic injury (Laumet et al., 2015). Inhibition
or deletion of G9a also markedly reduced neuropathic
hyperalgesia. Notably, baseline REST levels in neurons are
low, but neuropathic injury and inﬂammation triggers REST
expression (Mucha et al., 2010; Uchida et al., 2010; Rose
et al., 2011; Willis et al., 2016), which, in turn, drives the neu-
ropathic remodelling.
Of note is the fact that M channel expression in neuro-
pathic ﬁbres is reduced, but not abolished (Rose et al., 2011;
Cisneros et al., 2015). Accordingly, M channel openers are
still efﬁcacious in alleviating neuropathic pain symptoms,
presumably by acting on the remaining Kv7 channels to sta-
bilize the Erest and reduce ﬁring in the affected ﬁbres. Thus,
retigabine strongly suppressed the spontaneous activity of
neuropathic ﬁbres (Bernal et al., 2016), and thermal
hyperalgesia produced by PSNL in rats was effectively allevi-
ated by an injection of ﬂupirtine directly into the neuroma
(an effect that was reversed by XE991) (Rose et al., 2011). It
has to be noted that an increase in Kv7.2-positive nodes of
Ranvier in nerve-end neuromas of mice with neuropathic in-
jury (saphenous nerve transection) has also been reported
(Roza et al., 2011; Cisneros et al., 2015). Thus, while down-
regulated in the soma and elsewhere, remaining M channels
may actually be pooled at the sites of ectopic activity (e.g. at
neuroma nerve stubs), as a compensatory mechanism to off-
set spurious nerve activity. Such an effect would represent
an additional mechanism for anti-nociceptive efﬁcacy of pe-
ripherally applied M channel openers.
Cancer pain
Tumours often trigger pain via a combination of inﬂamma-
tory, neuropathic, ischaemic and tissue compression mecha-
nisms and also by chemical mediators released by cancer
cells (Prinsloo et al., 2013). Systemic administration of
ﬂupirtine displayed analgesic efﬁcacy in a rat model of pros-
tate bone metastasis (Kolosov et al., 2012), suggesting that a
general dampening of excitability within the pain pathways
via M channel potentiation might have potential as a treat-
ment for cancer pain.
As in the case of neuropathic pain, a marked down-
regulation of Kv7.2 and Kv7.3 channel abundance and a
reduction ofM current amplitudes were reported in DRG neu-
rons in a rat model of bone cancer pain (Zheng et al., 2013);
these effects were also accompanied by a hyperexcitable state
of the DRG neurons. In a follow-up study, the same group also
showed that the excitability of the C-ﬁbre-synapsed WDR
neurons in the dorsal horn is also enhanced in the rats devel-
oping bone cancer and this effect was also attributed, at least
in part, to the M channel suppression (although in the latter
study, it was not clear, whether the M current was down-
regulated in the C-ﬁbre terminals or in the WDR neurons
themselves, or at both locations) (Cai et al., 2015). Systemic
(Zheng et al., 2013) or intrathecal (Cai et al., 2015) retigabine
alleviated mechanical allodynia and thermal hyperalgesia in-
duced by bone cancer and also reduced hyperexcitability of
both DRG and WDR DH neurons. Similar to the neuropathic
pain models (Rose et al., 2011), despite the down-regulation
of M channel activity/expression, retigabine and ﬂupirtine
were still efﬁcacious in alleviating cancer pain even when ap-
plied locally (e.g. intrathecally).
M channel openers
Due to the extensive expression of Kv7 channels in the ner-
vous and cardiovascular systems and their strong effects on
excitability, the therapeutic potential of these channels is
not limited to pain but also includes epilepsy, anxiety
(Gribkoff, 2008), stroke (i.e. as a protection against
excitotoxicity) (Gamper et al., 2006; Bierbower et al., 2015),
smooth muscle disorders (Stott et al., 2014) and other dis-
eases. It is therefore not surprising that there is a large drive,
both in industry and academia, to identify potent and selec-
tive M channel openers. Conveniently, M channels present
an unusually rich substrate for pharmacological modulation,
and literally thousands of openers acting via various distinct
mechanisms have already been identiﬁed. World Intellectual
Property Organization lists well over 2 hundred patents re-
lated to M channel openers. Progress in M channel pharma-
cology has been discussed in several recent reviews
(Gribkoff, 2008; Miceli et al., 2008; Du and Gamper, 2013;
Grunnet et al., 2014); known mechanisms of potentiation
and binding sites for major classes of M channel openers were
reviewed by us recently (Du and Gamper, 2013); therefore,
here we will just brieﬂy outline the main classes of M channel
openers, which display analgesic activity, as well as some ma-
jor recent developments.
The prototypical M channel openers retigabine
(ezogabine) and ﬂupirtine (katadolon, awegal) belong to
triaminopyridines (Figure 3A, B); these compounds are po-
tent but relatively non-selective Kv7 openers that activate all
Kv7 subunits except of Kv7.1, with Kv7.3 being the most sen-
sitive subunit (Tatulian et al., 2001; Tatulian and Brown,
Figure 3
Chemical structures of retigabine and its analogues.
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2003; Schenzer et al., 2005; Wuttke et al., 2005). Flupirtine
has been used clinically in Europe since 1984 as a centrally
acting nonopioid analgesic for postoperative, traumatic and
cancer pain; it also has muscle-relaxant activity. The analgesic
efﬁcacy of ﬂupirtine is comparable to that of non-steroidal
anti-inﬂammatory drugs such as ibuprofen (Miceli et al.,
2008). Although ﬂupirtine was reported to affect NMDA
and GABA receptors (Miceli et al., 2008), little direct
evidence exists and it is believed that its analgesic effect is
mainly related to its activity as an M channel opener
(Devulder, 2010). Retigabine is a clinically approved antiepi-
leptic drug (Stafstrom et al., 2011), but it also consistently dis-
plays analgesic efﬁcacy in multiple animal pain models such
as temporomandibular joint pain (Xu et al., 2010), visceral
pain (Hirano et al., 2007), carrageenan-induced hyperalgesia
(Passmore et al., 2003), trigeminal neuropathy (Abd-Elsayed
et al., 2015), bone cancer pain (Zheng et al., 2013). The
clinical use of retigabine has been recently restricted to ad-
junctive treatment of drug-resistant partial onset seizures
(and only if other treatments have failed or could not be tol-
erated; Daniluk et al., 2016) due to signiﬁcant risks of skin dis-
coloration, retinal pigmentation, urinary retention, sedation
and QTc prolongation (Daniluk et al., 2016). Nevertheless,
retigabine remains a useful research tool and a ‘benchmark’
drug in animal pain models. Its mechanism of action is also
fairly well understood. The binding site of retigabine resides
within the cytosolic region between S5 and S6 transmem-
brane domains of Kv7 channels and contains a critical
tryptophan (W236 in Kv7.2), which is absent in Kv7.1
(Schenzer et al., 2005; Wuttke et al., 2005). Biophysically
triaminopyridines induce a large shift in channel voltage-
dependence towards negative voltages (i.e. retigabine shifts
half-maximal activation voltage of Kv7.2/Kv7.3 multimers
by more than 30 mV); additionally, these compounds in-
crease macroscopic steady-state K+ conductance at saturating
voltages (Tatulian et al., 2001; Tatulian and Brown, 2003;
Schenzer et al., 2005; Wuttke et al., 2005; Linley et al., 2012b).
Kv7 channels are widely expressed within the CNS, PNS
and vasculature, yet their subunit distribution is not uniform.
While Kv7.2/Kv7.3 multimeric channels are believed to dom-
inate the CNS, Kv7.4 is highly expressed speciﬁcally in audi-
tory pathways (as well as in a subpopulation of rapidly
adapting cutaneous mechanoreceptors; Heidenreich et al.,
2012; see above). Kv7.1 is mostly expressed in the heart and
epithelia (but not in neurons), while vascular smooth mus-
cles more abundantly express Kv7.5, Kv7.4 and their
multimers (reviewed in Gamper and Shapiro, 2015). There-
fore, openers such as retigabine, which discriminate poorly
between Kv7 subunits, are likely to have multiple ‘on-target’
side effects. Drugs with higher subunit selectivity ‘tailored’
towards speciﬁc cell types are needed to achieve more speciﬁc
pharmacological actions. Indeed, recent efforts in academia
and industry have been focused on discovering new drugs
or the reﬁnement of existing compounds towards better se-
lectivity and higher potency.
Several groups have performed structure–activity
relationship (SAR) analyses of retigabine to produce more po-
tent and selective derivatives. Thus, compounds PF-05020182
(Figure 3C) (Davoren et al., 2015) and NS15370 (Figure 3D)
(Dalby-Brown et al., 2013), which are ~10 and ~30 fold more
potent than retigabine, were synthesized; these are ineffective
against Kv7.1 but do activate Kv7.4 and Kv7.5 channels with
comparable potency to that of Kv7.2/Kv7.3. Thanos
Tzounopoulos’ group used the SAR approach to generate sev-
eral improved retigabine derivatives. By introducing a CF3-
group at the 4-position of the benzylaminemoiety and a ﬂuo-
rine at the 3-position of the aniline ring (Figure 3E), they gen-
erated a compound (RL648_81) which is over 15 times more
potent than retigabine at Kv7.2/Kv7.3 channels (EC50 0.2 μM
vs. ~3 μM) and does not affect Kv7.4 and Kv7.5 (Kumar et al.,
2016). Another recent compound, ICA-069673 (and related
derivatives such as ICA-27243 and ztz series compounds), dis-
plays remarkable selectivity for Kv7.2 over Kv7.3 (Figure 3F)
(Wickenden et al., 2008; Gao et al., 2010; Wang et al., 2016).
Other M channel openers include acrylamides known as
compounds (S)-1 and (S)-2 (Wu et al., 2004a,b,c, 2013;
L’Heureux et al., 2005) developed by Bristol-Myers Squibb.
Acrylamides share the site of action and speciﬁcity proﬁle
with retigabine (Bentzen et al., 2006) and display analgesic
efﬁcacy in rodent models of migraine (Wu et al., 2004a), in-
ﬂammatory and neuropathic pain (Wu et al., 2013). A QO
series of openers is based on pyrazolo[1,5-a]pyrimidin-
7(4H)-one (Jia et al., 2011; Qi et al., 2011; Zhang et al.,
2012; Teng et al., 2016); the lead compound, QO-58 (and
QO-58-lysine, which has improved bioavailability), has
analgesic efﬁcacy in neuropathic and inﬂammatory pain
models (Zhang et al., 2012; Teng et al., 2016). QO-58 poten-
tiates all Kv7 channels except Kv7.3. Benzimidazoles, such as
compound B1 (Zhang et al., 2011a; Du and Gamper, 2013),
have high selectivity for Kv7.2 over Kv7.3, Kv7.4 and Kv7.5.
Like the QO series, benzimidazoles do not require W236 for
their action on Kv7 channels (reviewed in Du and Gamper
(2013). In addition, adamantyl derivatives (Fritch et al.,
2010), N-phenilanthranilic acid derivatives, for example,
meclofenamic acid, diclofenac and related compounds
(Peretz et al., 2005; Peretz et al., 2007; Brueggemann et al.,
2009; Peretz et al., 2010), tannic acid (Zhang et al., 2015)
and a Rho kinase inhibitor fasudil (Zhang et al., 2016) were
identiﬁed as M channel openers. Of these, fasudil is perhaps
unique as it selectively activates Kv7.4 and Kv7.4/Kv7.5
channels but not the other Kv7 subunits. A zinc coordination
complex, zinc pyrithione, has also been suggested to
display Kv7 channel opener activity (Xiong et al., 2007), but
it appears that the channel potentiation in this case is
produced by intracellular zinc, whereas pyrithione acts as a
zinc ionophore (Gao et al., 2017).
Where is the site of analgesic action of
M channel openers?
M channel openers display analgesic efﬁcacy when adminis-
tered peripherally (e.g. plantar paw injections) (Linley et al.,
2008; Liu et al., 2010; Huang et al., 2016a), injected into the
neuroma site (Rose et al., 2011), focally applied to DRG (Du
et al., 2014) or administered intrathecally (Cai et al., 2015)
or systemically (reviewed in Du and Gamper (2013). Interest-
ingly, one recent study has demonstrated that even when
given orally, the analgesic action of retigabine is almost exclu-
sively peripheral (Hayashi et al., 2014). Thus, most central ef-
fects of oral retigabine (anticonvulsant effect, impairedmotor
coordination, reduced exploratory behaviour) were
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effectively precipitated by central (i.c.v.) application of
XE991. Yet the analgesic effect was not affected. The likeli-
hood therefore is that the main site of analgesic action of
retigabine is within the peripheral ﬁbres.
As discussed above, functional M channels have been
shown to be present in all major sensory nerve compartments
(peripheral and central terminals, soma, axon). Thus, theoreti-
cally, M channel activation can suppress the generation, propa-
gation and transmission of nociceptive signals to the CNS.
Experimental data suggest that potentiation ofM channel
activity at the nociceptive terminals in the skin with
retigabine, ﬂupirtine or other openers does indeed reduce
basal sensitivity to thermal and mechanical stimuli
(Passmore et al., 2012; Vetter et al., 2013; Huang et al.,
2016a) and alleviates the nociceptive effects of various pe-
ripherally applied algogenic stimuli (Linley et al., 2008; Liu
et al., 2010; Passmore et al., 2012; Vetter et al., 2013; Hayashi
et al., 2014; Huang et al., 2016a; Peiris et al., 2017). This
Figure 4
Biophysical model of a small-diameter unmyelinated DRG neuron. (A) Shown on the left is a drawing of soma and stem axon of small-diameter cat
DRG neuron (based on micrograph from Ha, 1970); on the right are the morphological dimensions of the model neuron. (B) Enhancing the ac-
tivity of M channels with virtual retigabine (30 mV shift in activation curve, 1.5 fold increase in conductance density) hyperpolarized the t-junc-
tion and reduced (at initial IM density of 0.9 pA/pF) or abolished (at initial IM density of 1.05 pA/pF) spike propagation in the model neuron. (C)
Retigabine reduces the likelihood of spike generation in the central axon. Action potential amplitude is plotted as function of distance along
100 μm of peripheral and central axon sections with the t-junction in the middle. In control conditions, spike amplitude decreases when ap-
proaching the t-junction, due to the impedance load of the bifurcation. On the central side of the t-junction, a delayed action potential develops
and grows with distance from the t-junction. When retigabine is added, the spike amplitude in the peripheral axon is not signiﬁcantly affected; in
contrast, the spike fails on the central side of the t-junction and its decay is recorded (modiﬁed from Du et al., 2014, with permission).
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suggests that nociceptive nerve endings are indeed one of the
sites for the analgesic efﬁcacy of the openers.
Intrathecal application of M channel openers also pro-
duces an analgesic effect (Cai et al., 2015), suggesting that
the transmission of nociceptive signals to the spinal cord
can also be controlled by M channels. Yet, in this case, it is
hard to pinpoint the site of action exactly, as DRG, dorsal
roots, central terminals of the afferent ﬁbres and the spinal
circuitry are all exposed to an intrathecally applied drug.
Interestingly, a focal injection of ﬂupirtine onto un-
injured sciatic nerve did not signiﬁcantly affect noxious heat
sensitivity of the plantar surface of the paw (Rose et al., 2011),
suggesting that the propagation of peripheral nociceptive sig-
nals through the axons is perhaps less affected by M channel
activity, as compared to their initiation or transmission. How-
ever, there is one site within the axon of a somatosensory
neuron where propagation of the peripherally-derived action
potentials can be effectively disrupted by M channel activa-
tion, and it is the point at which the axon, emanating from
the cell body, bifurcates into the peripheral and central
branches, the t-junction (Figures 2 and 4A). The bifurcation
of an afferent axon is a point of lowest safety factor for action
potential propagation (Stoney, 1985; Luscher et al., 1994;
Debanne, 2004; Gemes et al., 2013; Du et al., 2014; Sundt
et al., 2015), and both experiments and computer modelling
suggest that hyperpolarization of a t-junction (e.g. with
retigabine) can result in the failure of an action potential to
propagate (Du et al., 2014; Sundt et al., 2015; Figure 4).
In order to better understand the ﬁltering role of the
t-junction, we recently developed a computational model of a
small-diameter, unmyelinated mammalian DRG neuron (Du
et al., 2014; Sundt et al., 2015; Figure 4) based on available
anatomical data (Ha, 1970; Suh et al., 1984; Hoheisel and
Mense, 1987). The model revealed that due to the electrotoni-
cally short stem axon (Figure 4A), somatic/perisomatic hyper-
polarization in combination with the increased membrane
conductance, produced by ‘M channel’ potentiation (or by
other similar manoeuvres), further lowered the safety factor at
the t-junction and, as a result, interfered with action potential
propagation (Figure 4B, C). Without a t-junction, the safety
factor in the axon is relatively high, and comparable ion chan-
nel modulation, for example, in the central axon distal to the
t-junction, had no effect on spike transmission. The model
explains well why an injection of ﬂupirtine into the sciatic
nerve did not signiﬁcantly affect pain thresholds (Rose et al.,
2011). Whereas, as predicted by the model, focal infusion of
retigabine directly on to the L5 DRG in vivo (via an implanted
cannula) strongly alleviated pain produced by a hind paw
injection of bradykinin (Du et al., 2014).
In summary, current evidence suggests that the
antinociceptive effect of M channel openers is mostly localized
to peripheral nociceptive ﬁbres, and within these, the action is
most likely localized to the sites of action potential initiation
(peripheral nerve endings, ectopic sites), propagation (the
t-junctions) and transmission (central terminals).
Conclusions and future perspectives
The ﬁfteen or so years since the ﬁrst report of the presence of
functional M channels in peripheral somatosensory neurons
(Passmore et al., 2003) has seen rapid progress in our under-
standing of the role these channels play in nociception. It is
now ﬁrmly established that (i) the M current is an important
control mechanism, which ‘clamps’ Erest of nociceptors and
sets their resting excitability parameters (e.g. threshold cur-
rent); (ii) M channel openers consistently display analgesic
efﬁcacy in most experimental pain models; and (iii) both
acute inhibition of M channel activity or long-term down-
regulation of M channel abundance (e.g. via the epigenetic
mechanisms) often drives nociceptors into an overexcitable
state, which is associated with acute or chronic pain. M chan-
nels are therefore a validated drug target for the treatment of
pain, and many pharmaceutical companies are investing in
the development of new M channel openers. There are,
however, a few issues that hamper the progress. Particularly,
(i) there is still no clarity with regards to the M channel
subunit expression proﬁle in known subpopulations of sen-
sory neurons and (ii) we are still short of the set of truly
subunit-selective M channel openers with good drug-like
properties. Both these shortcomings should be solved in or-
der to be able to target M channels in crucial subpopulations
of nociceptors more speciﬁcally.
Another consideration regarding possible reﬁnement of
current drug design strategies arises from the fact that while
current therapeutic M channel openers are designed for the
systemic application (i.e. oral), the analgesic efﬁcacy of such
drugs is most likely peripheral. It is also important to point
out that the dorsal roots and the central terminals of the no-
ciceptive ﬁbres are protected by the blood–brain barrier
(BBB) within the spinal cord, whereas the afferent axons
within the peripheral nerves are protected by the blood-nerve
barrier (BNB). Yet spinal ganglia themselves have no such bar-
rier and are exposed to the circulation to a signiﬁcant extent
(Devor, 1999). Since somatic/perisomatic M channels are ca-
pable of controlling action potentials propagating through
the t-junctions of nociceptors, it seems logical to propose that
M channel openers with poor BBB/BNB permeability can still
have analgesic efﬁcacy due to their action within peripheral
ganglia, yet the central side effects of such compounds could
be signiﬁcantly reduced. Future research will test if such a
strategy can be implemented.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.
org, the common portal for data from the IUPHAR/BPS Guide
to PHARMACOLOGY (Southan et al., 2016), and are perma-
nently archived in the Concise Guide to PHARMACOLOGY
2015/16 (Alexander et al., 2015a,b,c,d).
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